Mylan Sharpens Injectables Business With Agila Buy For $1.6 Billion
This article was originally published in The Pink Sheet Daily
Stream of highly profitable drug launches in the U.S. by India’s Agila attracted Mylan to make an aggressive bid, leapfrogging it from the bottom 10 rank to a leading position in the injectables space. Drug shortages add to Mylan opportunity in bringing in Agila’s injectables. Deal includes added $250 million in potential milestone payments.